[어바웃 C] SK바사, 백신통 영입…'개발 실행력' 병목 해소 카드

SK Bioscience's appointment of a vaccine expert and organizational restructuring signals a strategic pivot toward accelerating its own vaccine pipeline commercialization, particularly GBP410. This move is critical as the company seeks to rebalance its portfolio away from contract manufacturing services (CDMO, 71.5% of 2025 revenue) and restore its vaccine-focused biotech identity in an increasingly competitive market.